Authoritative investigators active in the discovery, development, and application of biological anti-infective agents concisely review their use and potential in preventing and treating human disease. Focusing on biotherapeutic entities that have been tested in controlled studies, the prominent experts illuminate the scientific underpinnings of their therapeutic power, assess their possible risks in the treatment of infectious diseases, and outline the research needed to better define their effectiveness. In addition, they also consider how biotherapeutic agents may be genetically engineered for maximum intestinal and vaginal production of bioactive substances in vivo. Biotherapeutic Agents and Infectious Diseases brings together all the evidence needed to understand and capitalize on the considerable promise of this significant new class of biotherapeutic entities.

Examining the enormous potential of microbiome manipulation to improve health Associations between the composition of the intestinal microbiome and many human diseases, including inflammatory bowel disease, cardiovascular disease, metabolic disorders, and cancer, have been elegantly described in the past decade. Now, whole-genome sequencing, bioinformatics, and precision gene-editing techniques are being combined with centuries-old therapies, such as fecal microbiota transplantation, to translate current research into new diagnostics and therapeutics to treat complex diseases. Bugs as Drugs provides a much-needed overview of microbes in therapies and will serve as an excellent resource for scientists and clinicians as they carry out research and clinical studies on investigating the roles the microbiota plays in health and disease. In Bugs as Drugs, editors Robert A. Britton and Patrice D. Cani have assembled a fascinating collection of reviews that chart the history, current efforts, and future prospects of using microorganisms to fight disease and improve health. Sections cover traditional uses of probiotics, next-generation microbial therapeutics, controlling infectious diseases, and indirect strategies for manipulating the host microbiome. Topics presented include: How well-established probiotics support and improve host health by improving the composition of the intestinal microbiota of the host and by modulating the host immune response. The use of gene editing and recombinant DNA techniques to create tailored probiotics and to characterize next-generation beneficial microbes. For example, engineering that improves the anti-inflammatory profile of probiotics can reduce the number of colonic polyps formed, and lactobacilli can be transformed into targeted delivery systems carrying therapeutic proteins or bioengineered bacteriophage. The association of specific microbiota composition with colorectal cancer, liver diseases, osteoporosis, and inflammatory bowel disease. The gut microbiota has been proposed to serve as an organ involved in regulation of inflammation, immune function, and energy homeostasis. Fecal microbiota transplantation as a promising treatment for numerous diseases beyond C. difficile infection. Practical considerations for using fecal microbiota transplantation are provided, while it is acknowledged that more high-quality evidence is needed to ascertain the importance of strain specificity in positive treatment outcomes. Because systems biology approaches and synthetic engineering of microbes are now high-throughput and cost-effective, a much wider range of therapeutic possibilities can be explored and vetted. If you are looking for online access to the latest clinical microbiology content, please visit www.wiley.com/learn/clinmicronow.

“Uses [pneumonia] as a vehicle for examining the evolution of therapeutics in America between the ‘Golden Age of Microbiology’ and the ‘Age of Antibiotics.’”—Isis Focusing largely on the treatment of pneumonia in first half of the century with type-specific serotherapy, clinician-historian Scott H. Podolsky provides insight into the rise and clinical evaluation of therapeutic “specifics,” the contested domains of private practice and public health, and—as the treatment of pneumonia made the transition from serotherapy to chemotherapy and antibiotics—the tempo and mode of therapeutic change itself. Type-specific serotherapy, founded on the tenets of applied immunology, justified by controlled clinical trials, and grounded in a novel public ethos, was deemed revolutionary when it emerged to replace supportive therapeutics. With the advent of the even more revolutionary sulfa drugs and antibiotics, pneumonia ceased to be a public health concern and became instead an illness treated in individual patients by individual physicians. Podolsky describes the new therapeutics and the scientists and practitioners who developed and debated them. He finds that, rather than representing a barren era in anticipation of some unknown transformation to come, the first decades of the twentieth-century shaped the use of, and reliance upon, the therapeutic specific throughout the century and beyond. This intriguing study will interest historians of medicine and science, policymakers, and clinicians alike. “Podolsky’s scholarship is awesome, and his grasp of the philosophical and sociologic context of the issues considered make this an important work.” —New England Journal of Medicine “This thoroughly documented, carefully written book is a landmark analysis . . . It should be read by everyone who is involved in research and therapeutic development.” —JAMA

This book illustrates the successful partnership of chemistry and biology to advance successful biotherapeutic modalities. Molecular design to create function is common to both chemical and molecular biology, and this text highlights recent developments from these disciplines that have delivered drugs, clinical candidates or significantly advanced biotherapeutic approaches. Biotherapeutics are often considered to be beyond the reach of the medicinal chemist, but this book demonstrates that chemistry has an essential role in the future success of this area, by explaining and describing the chemical biology technologies that underpin specific therapeutic advances and demonstrating the unique value of molecular design and understanding. Covering topics such as selective protein modification, immunopharmacotherapy, chemically programmed vaccinations, nanobodies and antibodies, this book provides essential reading for medicinal and pharmaceutical chemists working in both industry and academia.

Infectious diseases have existed longer than us, as long as us, or are relatively newer than us. It may be the case that a disease has existed for many, many years but has only recently begun affecting humans. At the turn of the century the number of deaths caused by infections in the United States had been falling steadily but since the '80s has seen an increase. In the past 30 years alone 37 new pathogens have been identified as human disease threats and 12% of known human pathogens have been classified as either emerging or remerging. Whatever the story, there is currently a "war" on infectious diseases. This war is simply the systematic search for the microbial "cause" of each disease, followed by the development of antimicrobial therapies. The "war" on infectious diseases, however, must be revisited in order to develop a more realistic and detailed picture of the dynamic interactions among and between host organisms and their diverse populations of microbes. Only a fraction of these microbes are pathogens. Thus, in order to explore the crafting of a new metaphor for host-microbe relationships, and to consider how such a new perspective might inform and prioritize biomedical research, the Forum on Microbial Threats of the Institute of Medicine (IOM) convened the workshop, Ending the War Metaphor: The Changing Agenda for Unraveling the Host-Microbe Relationship on March 16-17, 2005. Workshop participants examined knowledge and approaches to learning about the bacterial inhabitants of the human gut, the best known host-microbe system, as well as findings from studies of microbial communities associated with other mammals, fish, plants, soil, and insects. The perspective adopted by this workshop is one that recognizes the breadth and diversity of host-microbe relationships beyond those relative few that result in overt disease. Included in this summary are the reports and papers of individuals participating in the Forum as well as the views of the editors.

Probiotics in The Prevention and Management of Human Diseases: A Scientific Perspective addresses the use of probiotics and their mechanistic aspects in diverse human diseases. In particular, the mechanistic aspects of how these probiotics are involved in mitigating disease symptoms (novel approaches and immune-mechanisms induced by Probiotics), clinical trials of certain probiotics, and animal model studies will be presented through this book. In addition, the book covers the role of probiotics in prevention and management aspects of crucial human diseases, including multidrug resistant infections, hospital acquired infections, allergic conditions, autoimmune diseases, metabolic disorders, gastrointestinal diseases, neurological disorders, and cancers. Finally, the book addresses the use of probiotics as vaccine adjuvants and as a solution for nutritional health problems and describes the challenges of using probiotics in management of human disease conditions as well as their biosafety concerns. Intended for nutrition researchers, microbiologists, physiologists, and researchers in related disciplines as well as students studying these topics require a resource that addresses the specific role of probiotics in the prevention and management of human disease. - Contains information on the use of probiotics in significant human diseases, including antibiotic resistant microbial infections - Presents novel applications of probiotics, including their use in vaccine adjuvants and concept of pharmabiotics - Includes case studies and human clinical trials for probiotics in diverse disease conditions and explores the role of probiotics in mitigation of the symptoms of disease

This textbook includes the recent progresses and scientific knowledge from the leading experts in different approaches to control, diagnosis, and management depending on resources and facilities available. This book has been written by our colleagues from all over the world. This book is divided into six sections. Each section supplies particularly sexually transmitted infections, diagnostics, microorganism types, pathogenesis, and treatment options. Essential points in publishing this book are to improve our knowledge about sexually transmitted infections and new treatment modalities. One chapter of the book is devoted to viral infections and their treatment. We think that this textbook will serve as a comprehensive guide to many physicians dealing with sexually transmitted infections in their clinical practice. It will hopefully be a precious source for dermatologists, educators, other physicians, and medical students.

A comprehensive primer and reference, this book provides pharmacists and health practitioners the relevant science and policy concepts behind biologics, biosimilars, and biobetters from a practical and clinical perspective. Explains what pharmacists need to discuss the equivalence, efficacy, safety, and risks of biosimilars with physicians, health practitioners, and patients about Guides regulators on pragmatic approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical evidence Balances scientific information on complex drugs with practical information, such as a checklist for pharmacists

This next volume in the series will provide up to date Information and discussion on future approach to control several challenging Infectious Disease worldwide. The past decade has been highlighted by numerous advances in research of medical scientific knowledge. medical technology and the biological and diagnostic techniques-but somewhat less dramatic changes or improvement in management of medical conditions. This volume will address some of the emerging issues, challenges, and controversies in Infectious Diseases.

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.